See more : Aeroports de Paris SA (AEOXF) Income Statement Analysis – Financial Results
Complete financial analysis of MiNK Therapeutics, Inc. (INKT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MiNK Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- MT Højgaard Holding A/S (MTHH.CO) Income Statement Analysis – Financial Results
- CareRay Digital Medical Technology Co., Ltd. (688607.SS) Income Statement Analysis – Financial Results
- Datang Environment Industry Group Co., Ltd. (1272.HK) Income Statement Analysis – Financial Results
- GX Acquisition Corp. II (GXIIW) Income Statement Analysis – Financial Results
- GO Acquisition Corp. (GOAC-UN) Income Statement Analysis – Financial Results
MiNK Therapeutics, Inc. (INKT)
About MiNK Therapeutics, Inc.
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 2.70B | 0.00 | 0.00 | 689.63K |
| Cost of Revenue | 204.62K | 30.95B | 28.36B | 55.06K | 0.00 |
| Gross Profit | -204.62K | -28.24B | -28.36B | -55.06K | 689.63K |
| Gross Profit Ratio | 0.00% | -1,044.26% | 0.00% | 0.00% | 100.00% |
| Research & Development | 15.49M | 23.12M | 13.97M | 9.51M | 19.65M |
| General & Administrative | 7.43M | 7.83M | 4.64M | 1.29M | 3.83M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.43M | 7.83M | 4.64M | 1.29M | 3.83M |
| Other Expenses | 0.00 | 2.70M | -9.53M | -3.00M | 551.24K |
| Operating Expenses | 22.92M | 30.95M | 18.61M | 10.80M | 23.48M |
| Cost & Expenses | 22.92M | 30.95M | 18.61M | 10.80M | 23.48M |
| Interest Income | 463.26K | 253.32K | 2.43K | 2.44K | 1.56K |
| Interest Expense | 0.00 | 253.32K | 2.43M | 2.44M | 1.56M |
| Depreciation & Amortization | 204.62K | 121.75K | 77.96K | 55.06K | 36.82K |
| EBITDA | -22.25M | -30.83M | -27.70M | -13.74M | -22.20M |
| EBITDA Ratio | 0.00% | -1.14% | 0.00% | 0.00% | -3,219.79% |
| Operating Income | -22.92M | -30.95M | -28.36M | -14.64M | -22.28M |
| Operating Income Ratio | 0.00% | -1.14% | 0.00% | 0.00% | -3,231.39% |
| Total Other Income/Expenses | 463.25K | 2.96M | -1.85M | -1.60M | -1.52M |
| Income Before Tax | -22.46M | -27.99M | -30.21M | -16.24M | -23.80M |
| Income Before Tax Ratio | 0.00% | -1.03% | 0.00% | 0.00% | -3,451.46% |
| Income Tax Expense | 0.00 | -3.21M | -7.10M | -560.38K | 2.11M |
| Net Income | -22.46M | -24.78M | -23.11M | -15.68M | -25.91M |
| Net Income Ratio | 0.00% | -0.92% | 0.00% | 0.00% | -3,757.73% |
| EPS | -0.65 | -0.74 | -0.69 | -0.47 | -0.78 |
| EPS Diluted | -0.65 | -0.74 | -0.69 | -0.47 | -0.78 |
| Weighted Avg Shares Out | 34.36M | 33.67M | 33.48M | 33.09M | 33.09M |
| Weighted Avg Shares Out (Dil) | 34.36M | 33.67M | 33.48M | 33.09M | 33.09M |
MiNK Therapeutics to Participate in September Investor Conferences
NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases,...
MiNK Therapeutics Reports Second Quarter 2023 Results
- Randomized Phase 2 Trial in 2L Metastatic Gastric Cancer Planned to Launch at Memorial Sloan Kettering Cancer Center
MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update
NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases,...
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases,...
MiNK Therapeutics, Inc. (INKT) Q1 2023 Earnings Call Transcript
MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Zack Armen – Head-Investor Relations Jennifer Buell – President and Chief Executive Officer Marc Van Dijk – Chief Scientific Officer Christine Klaskin...
MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results
NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases,...
MiNK Therapeutics, Inc. (INKT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for MiNK Therapeutics, Inc. (INKT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal...
MiNK Therapeutics, Inc. (INKT) Upgraded to Buy: What Does It Mean for the Stock?
MiNK Therapeutics, Inc. (INKT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
MiNK Therapeutics: iNKT Therapy Data Should Drive Stock Price Up
AgenT-797 data presented at SITC in November was encouraging. More AgenT-797 cancer data expected at AACR on April 18.
MiNK Therapeutics, Inc. (INKT) Q4 2022 Earnings Call Transcript
MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q4 2022 Results Conference Call March 21, 2023 8:30 AM ET Company Participants Zack Armen - Head of Investor Relations at MiNK Jennifer Buell - President and Chief Executive Officer Christine Klaskin - Principal Financial...
Source: https://incomestatements.info
Category: Stock Reports